Article
Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
Oncogene - 10 Apr 2008
Lin K, Rockliffe N, Johnson G G, Sherrington P D, Pettitt A R
Abstract excerpt
In chronic lymphocytic leukaemia (CLL), mutation/deletion of TP53 is strongly associated with early disease progression, resistance to chemotherapy and short patient survival. Consequently, there is a pressing need to develop novel treatment protocols for this high-risk patient group. The present study was performed to evaluate Hsp90 inhibition as a possible therapeutic approach for such patients. Primary CLL...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.